Autologous peripheral blood-derived orthobiologics:Different types and their effectiveness in managing knee osteoarthritis  

作　　者：Ashim Gupta Vijay Kumar Jain 

机构地区：[1]Department of Orthopaedics and Regenerative Medicine,Future Biologics,Lawrenceville,GA 30043,United States [2]Department of Orthopaedics,South Texas Orthopaedic Research Institute(STORI Inc.),Laredo,TX 78045,United States [3]Department of Regenerative Medicine,BioIntegrate,Lawrenceville,GA 30043,United States [4]Department of Orthopaedics and Regenerative Medicine,Regenerative Orthopaedics,Noida 201301,India [5]Department of Orthopaedics,Atal Bihari Vajpayee Institute of Medical Sciences,Dr.Ram Manohar Lohia Hospital,Delhi 110001,New Delhi,India

出　　处：《World Journal of Orthopedics》2024年第5期400-403,共4页世界骨科杂志（英文版）

摘　　要：Knees are the most commonly impacted weight-bearing joints in osteoarthritis(OA),affecting millions of people worldwide.With increasing life spans and obesity rates,the incidence of knee OA will further increase,leading to a significant increase in the economic burden.Conventional treatment modalities utilized to manage knee OA have limitations.Over the last decade,the role of various autologous peripheral blood-derived orthobiologics(APBOs)for the treatment of knee OA has been extensively investigated.This editorial provided an overview and focused on defining and shedding light on the current state of evidence based on the most recent published clinical studies concerning the use of APBO for the management of knee OA.While numerous studies have demonstrated promising results for these preparations,a notable gap exists in the comparative analysis of these diverse formulations.This absence of head-to-head studies poses a considerable challenge for physicians/surgeons in determining the optimal preparation for managing knee OA and achieving sustained longterm results.Thus,more adequately powered,multicenter,prospective,doubleblind,randomized controlled trials with longer follow-ups are needed to establish the long-term efficacy and to aid physicians/surgeons in determining the optimal APBO for the management of knee OA.

关 键 词：Knee osteoarthritis Platelet-rich plasma Platelet lysate Autologous conditioned serum Gold-induced cytokine Plasma rich in growth factors Growth factor concentrate Autologous protein solution Platelet-rich fibrin Hyperacute serum 

分 类 号：R684.3[医药卫生—骨科学]